CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback